ExpreS2ion announces grant award for the development of new platforms for universal mucosal vaccines

Hørsholm, Denmark, March 3, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the MucoVax consortium has been awarded an Innovation Fund Denmark (IFD) Grand Solutions grant for the development of new platforms for universal mucosal vaccines in a 5-year research project in a collaboration between ExpreS2ion and University of Copenhagen. The award funding covers 71% of the research project and amounts to 29 MDKK (approx. 43 MSEK), of which ExpreS[2]ion directly is funded with 9.6 MDKK (approx. 14 MSEK). The IFD investment funds 67% of